OncLive SOSS

My Treatment Approach: Optimizing Treatment for Chronic GVHD - Episode 9

Recent Updates: REACH3, ROCKstar, and RWD

September 26, 2024

Shernan Holtan, MD, Haris Ali, MD, City of Hope

Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Differentiating Acute and Chronic Graft-vs-Host Disease

EP. 2: Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP. 3: Optimizing Chronic GVHD Therapy

EP. 4: Navigating Treatment Decisions in Chronic GVHD

EP. 5: Overview of Advanced Therapies in cGVHD

EP. 6: Overview of the ROCKstar Study

EP. 7: Considerations for Third-Line Treatment in Chronic GVHD

EP. 8: Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP. 9: Recent Updates: REACH3, ROCKstar, and RWD

EP. 10: AGAVE-201: Axatilimab for cGVHD

EP. 11: Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP. 12: Clinical Impact of Patient-Reported Outcomes in cGVHD

EP. 13: Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

Briefly discuss recent updates presented at ASH 2023 and TANDEM 2024:

3-year analysis of REACH3, ASH 2023
3-year follow-up of the ROCKstar study, TANDEM 2024

Brie fly discuss available real-world data (RWD) with ruxolitinib (Spałek A, et al. Pol Arch Intern Med. 2023) and ibrutinib (Chin KK, et al. Transplant Cell Ther. 2021;White J, et al. Transplant Cell Ther. 2023).

x